Leerink Partners analyst Mani Foroohar has reiterated their neutral stance on ALNY stock, giving a Hold rating on February 14.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mani Foroohar has given his Hold rating due to a combination of factors that impact Alnylam Pharma’s outlook. The company’s recent financial performance shows that product sales were consistent with prior announcements, and the guidance for the fiscal year 2025 remained unchanged. This stability suggests limited short-term growth potential, aligning with a Hold recommendation.
Furthermore, Alnylam’s pipeline developments and partnerships, such as the upcoming PDUFA dates for vutrisiran and fitusiran, present potential future revenue streams, but these are accompanied by uncertainties regarding their commercial success and the timing of launches. The ongoing R&D activities, like the nucresiran Phase 3 design and the KARDIA-3 trial, indicate progress but also imply that significant returns may not be immediate. Thus, the current market conditions and strategic decisions justify maintaining a neutral stance on the stock.
In another report released on February 14, Morgan Stanley also maintained a Hold rating on the stock with a $284.00 price target.
ALNY’s price has also changed slightly for the past six months – from $267.630 to $264.890, which is a -1.02% drop .